Abstract

Breast cancer is the most common female cancer. Its incidence is increasing rapidly in younger women, where early detection is infrequent, tumors tend to be more aggressive, and loss of productive years is greatest. High-dose chemotherapy with autologous hematopoietic progenitor cell support (AHPCS) has demonstrated effectiveness for poor-prognosis breast cancer patients. The focus of this ROl is the evaluation of AHPCS using CD34+ hematopoietic progenitor cells, which are then subjected to further manipulation(s). The goals of this project are to: l. Maximally decrease the amount of breast cancer in the autograft. 2. To produce rapid and durable marrow reconstitution in breast cancer patients receiving HDC. 3. To reduce the toxicity of infusing large volumes of unpurified AHPCS by using purified progenitor cells. 4. To develop ex vivo expansion of hematopoietic progenitors as a novel technology, and demonstrate its clinical utility.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA061508-03
Application #
2102242
Study Section
Special Emphasis Panel (SRC (57))
Project Start
1993-09-17
Project End
1997-06-30
Budget Start
1995-07-01
Budget End
1996-06-30
Support Year
3
Fiscal Year
1995
Total Cost
Indirect Cost

  Institution

Name
University of Colorado Denver
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045

  Publications

Muftuoglu, Muharrem; Olson, Amanda; Marin, David et al. (2018) Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy. N Engl J Med 379:1443-1451
Daher, May; Rezvani, Katayoun (2018) Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. Curr Opin Immunol 51:146-153
Robinson, Simon N; Thomas, Michael W; Simmons, Paul J et al. (2017) Non-fucosylated CB CD34+ cells represent a good target for enforced fucosylation to improve engraftment following cord blood transplantation. Cytotherapy 19:285-292
Alsuliman, Abdullah; Muftuoglu, Muharrem; Khoder, Ahmad et al. (2017) A subset of virus-specific CD161+ T cells selectively express the multidrug transporter MDR1 and are resistant to chemotherapy in AML. Blood 129:740-758
Mehta, Rohtesh S; Rezvani, Katayoun (2016) Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence 7:901-916
Sarvaria, Anushruti; Basar, Rafet; Mehta, Rohtesh S et al. (2016) IL-10+ regulatory B cells are enriched in cord blood and may protect against cGVHD after cord blood transplantation. Blood 128:1346-61
Torikai, Hiroki; Mi, Tiejuan; Gragert, Loren et al. (2016) Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application. Sci Rep 6:21757
Thompson, Philip A; Perera, Travis; Marin, David et al. (2016) Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma 57:1607-15
Sekine, Takuya; Marin, David; Cao, Kai et al. (2016) Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128:297-312
Naik, Swati; Nicholas, Sarah K; Martinez, Caridad A et al. (2016) Adoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytes. J Allergy Clin Immunol 137:1498-1505.e1

Showing the most recent 10 out of 59 publications